PathAI to Present at Digestive Disease Week
PathAI has recently launched updated versions of these tools on the AISight Translational Research platform1. IBD Explore v2.0 includes classification of additional cell types and tissue regions that were not included in prior versions, including macrophages, fibroblasts, and lymphoid aggregates. AIM-HI UC v2.0 now integrates PathAI's pathology universal transformer (PLUTO) foundation model and shows highly accurate performance, as highlighted in poster Su1904 at DDW.
Poster Details
Title: Consortium-driven Development of Pathology Foundation Model-based Approaches for Automated Scoring of Histopathology in Ulcerative Colitis (Abstract Number Su1904)
Session: IBD: Disease Activity Assessment and Monitoring
Date and Time: Sunday, May 4, 2025, from 12:30 – 1:30 p.m. PT
Presenter: Christina Jayson, Ph.D., Head of Inflammation and Immunology AI Product, PathAI
Title: Quantitative Histologic Features of the Inflammatory Microenvironment using Digital Pathology Prior to Adalimumab Treatment Associate with Response in Patients with Ulcerative Colitis (Abstract Number Tu2044)
Session: Emerging Tools and Technologies and In Vivo Models of GI Diseases
Date and Time: Tuesday, May 6, 2025, from 12:30 – 1:30 p.m. PT
Presenter: Christina Jayson, Ph.D., Head of Inflammation and Immunology AI Product, PathAI
Follow PathAI on LinkedIn for more updates from DDW 2025.
About PathAI
PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming diagnostic accuracy and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, please visit www.pathai.com.
Footnote
1AIM-HI UCTM, IBD ExploreTM, and AISight are For Research Use Only. Not for use in diagnostic procedures.
Company ContactElizabeth Stortielizabeth.storti@pathai.com
Media ContactDaniel DonatoLifeSci Communicationsddonato@lifescicomms.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
BTCMiner Redefines Crypto Investment with Safe, Efficient Cloud Mining Solutions
Coinbase, a leading cryptocurrency exchange, has seen its stock price soar to its highest level since its Nasdaq listing, reflecting growing investor confidence in the cryptocurrency sector. Amid this milestone, industry leaders are emphasizing the transformative potential of cryptocurrency cloud mining as a cornerstone of the investment landscape. A senior executive at Coinbase recently highlighted the critical role of cloud mining in addressing global economic challenges, stating, 'In an era of escalating global debt, persistent inflation, and diminishing economic freedom, cryptocurrency cloud mining offers a pathway to expand financial sovereignty and empower investors worldwide.' This perspective was first highlighted in a press release published by GlobeNewswire: BTCMiner: Ten Years of Safe and Stable Cloud Mining, Principal and Interest Guaranteed. The executive's remarks, shared on the BTCMiner platform, underscore the rising prominence of cloud mining as a low-barrier, high-potential investment avenue. As the cryptocurrency market evolves, platforms like BTCMiner are leading the charge by offering secure, efficient, and user-friendly solutions for investors seeking to capitalize on this innovative technology. BTCMiner: A Leader in Cryptocurrency Cloud Mining BTCMiner has emerged as one of the safest and most reliable cloud mining platforms in the industry, distinguished by its commitment to transparency, security, and efficiency. The platform offers a range of unique features designed to provide investors with peace of mind and consistent returns: Welcome Bonus: New users receive a $500 trial contract upon registration, enabling them to explore the platform's capabilities risk-free. This contract can be activated daily, offering a low-risk entry point for new investors. Regulatory Oversight: BTCMiner operates under the supervision of the UK's Financial Conduct Authority (FCA), ensuring regular audits and adherence to stringent regulatory standards. Principal and Interest Guarantee: The platform's innovative contract structure locks in both principal and returns, safeguarding investors against market volatility and ensuring predictable income. Energy Efficiency: BTCMiner employs an intelligent scheduling system that optimizes computing resources in real time, minimizing energy waste and enhancing mining efficiency. 'Cloud mining democratizes access to cryptocurrency investment,' said a prominent industry analyst. 'Platforms like BTCMiner are redefining the sector by combining cutting-edge technology with investor-focused features, making it easier than ever for individuals to participate in the crypto economy.' How to Get Started with BTCMiner Joining BTCMiner is a seamless process designed for accessibility and convenience: Create an Account: Visit the official website at provide an email address, and set a secure password to register. Claim Your Trial Contract: Upon successful registration, users instantly receive a $500 trial contract, which can be activated daily to generate returns. Select and Activate Contracts: Choose from a range of mining contracts, place an order with a single click, and monitor earnings in real time. Profits are automatically settled every 24 hours, ensuring transparency and ease of use. Explore additional contract options at to tailor your investment strategy Lucrative Referral Program BTCMiner also offers an attractive invitation rewards program, enabling users to earn passive income by sharing their exclusive referral links on social media. The program features a tiered reward structure: Level 1: Earn a 7% commission on the investments of directly referred users. Level 2: Receive a 2% commission on the investments of users referred by your direct referrals. Payments are processed in real time, providing an opportunity for users to generate additional income effortlessly. The Future of Cloud Mining Cloud mining represents a paradigm shift in cryptocurrency investment, characterized by its low entry threshold, cost-effectiveness, and automated management. By eliminating the need for expensive hardware or technical expertise, platforms like BTCMiner are making cryptocurrency mining accessible to a global audience. Looking ahead, BTCMiner is committed to further optimizing its resource allocation algorithms and enhancing mining efficiency to deliver even greater value to its users. As the cryptocurrency market continues to mature, cloud mining is poised to play a pivotal role in shaping the future of digital finance. With its robust features, regulatory compliance, and user-centric approach, BTCMiner is well-positioned to lead this transformation. Join the Cloud Mining Revolution Investors seeking to capitalize on the growing cryptocurrency market are encouraged to explore BTCMiner's offerings. New users can register today at to claim their $500 trial contract and begin their cloud mining journey. For additional information, contact BTCMiner's support team at info@ About BTCMiner BTCMiner is a leading cloud mining platform dedicated to providing secure, efficient, and accessible cryptocurrency mining solutions. With a focus on innovation and user satisfaction, BTCMiner is empowering investors to participate in the global cryptocurrency economy. Click here to download the BTCMiner platform APP Disclaimer The information provided in this press release does not constitute investment advice. Cryptocurrency investments carry inherent risks, and past performance is not indicative of future results. Users are advised. One project frequently cited in this context is BTCMiner, a platform that recently marked its tenth year in operation. Its longevity and stable performance were covered in a GlobeNewswire article, which highlighted BTCMiner's track record of delivering safe and consistent cloud mining services with a principal and interest guarantee.
Business Upturn
3 hours ago
- Business Upturn
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8 th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) — I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO) . Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. I-Mab plans to host a virtual investor event on Tuesday, July 8th (register here) to review these data. The Phase 1b data (NCT04900818) show a confirmed objective response rate (ORR) of 71% across all doses (12/17), and 83% (10/12) at doses selected for the ongoing dose expansion study (8 mg/kg and 12 mg/kg). Responses occurred in tumors with low levels of PD-L1 expression and/or Claudin 18.2 (CLDN18.2) expression, with favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 TRAE for increased liver enzymes. The data are based on the results of the dose escalation part of a Phase 1b study evaluating the givastomig combination as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ IHC staining intensity in ≥1% of tumor cells). The primary endpoint is safety. The study enrolled only patients in the U.S. 'The positive Phase 1b combination data presented at ESMO GI bolster our confidence in givastomig's potential to be a best-in-class Claudin 18.2 directed therapy. Givastomig has been well tolerated when combined with immuno-oncology and chemotherapy, has shown a high objective response rate, with rapid onset and durable responses that have deepened over time, supported by consistent pharmacokinetic data and soluble 4-1BB induction,' said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. 'In addition, we are optimistic about the results from the 8 mg/kg and 12 mg/kg doses. These doses showed an ORR of 83%, with consistent responses across PD-L1 and Claudin 18.2 expression levels, and a favorable overall safety profile. These data further our conviction in the ongoing Phase 1b dose expansion study. We believe givastomig has broad potential in a number of gastric cancer settings and look forward to continued advancement of the program.' 'I am encouraged by the response rates, as well as the deepening of responses over time, demonstrated by the givastomig combination regimen in the Phase 1b dose escalation study that we presented today at ESMO GI. Despite approved therapies, targeted treatment options for gastric cancers continue to be limited. While the data are early, givastomig combination therapy demonstrates a high response rate across Claudin 18.2 and PD-L1 expression levels,' said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital. 'In addition, I have been pleased to observe that givastomig has a favorable overall tolerability profile with a low level of gastrointestinal side effects — especially important for patients with gastric cancer. I look forward to participating in the ongoing givastomig clinical development program, and hope we may be able to expand the population of patients who may benefit from Claudin 18.2 directed agents.' Virtual Investor Event: Register (here) for the Post-ESMO GI 2025 Investor Event to be held on Tuesday, July 8th at 2:00 PM EDT. A replay of the webinar will be accessible on the Events page of the I-Mab website for 90 days. Fireside Chat Event with Lucid Capital Markets to Recap the Presentation: Tune in (here) for a fireside chat sponsored by Christopher Liu, PharmD, Managing Director at Lucid Capital Markets that will be accessible today at 2:00pm EDT on the Events page of the I-Mab website. A replay of the fireside chat will be available for 90 days. ESMO GI Presentation Details: A full copy of the ESMO GI presentation is available on the Publications and Presentations page of the I-Mab website here. Givastomig Phase 1b Dose Escalation Data Summary in 1L Gastric Cancers 17 advanced metastatic gastric cancer patients were treated with givastomig across the 5 mg/kg (n=5), 8 mg/kg (n=6), and 12 mg/kg (n=6) dose levels as of the May 15, 2025 data cutoff. All patients were efficacy evaluable Patient Characteristics: The 17 patients enrolled in the study were treatment naïve metastatic gastric, esophageal or gastroesophageal adenocarcinomas Patients were HER2-negative, Claudin 18.2-positive (defined as ≥1+ IHC staining intensity in ≥1% of tumor cells), regardless of PD-L1 expression levels All patients were enrolled at sites within the United States Efficacy Results: Confirmed Objective Response Rates (ORRs): 71% of patients (12/17) achieved a partial response (PR) per RECIST v1.1 5 mg/kg (2/5) 8 mg/kg (5/6) 12 mg/kg (5/6) At the doses selected for dose expansion (8 and 12 mg/kg), 83% (10/12) of patients achieved PRs 80% of patients (4/5) with CLDN18.2 expression below 75% (CLDN-Low) achieved a PR. The CLDN-Low response rate increased to 100% of patients (3/3) in the doses selected for expansion (8 and 12 mg/kg) The disease control rate (DCR) was 100% across the three dose levels Dose-dependent pharmacokinetics (PK) were observed, similar to monotherapy PK Patients also experienced a dose dependent induction of soluble 4-1BB, a positive indicator of T cell activation and engagement ORR: % (n) All (n=17) Cohorts Chosen for Expansion (8 and 12 mg/kg) (n=12) PD-L1 Any 71 (12/17) 83 (10/12) ≥5 82 (9/11) 89 (8/9) <5 50 (3/6) 67 (2/3) ≥1 73 (11/15) 82 (9/11) <1 50 (1/2) 100 (1/1) CLDN18.2 ≥75 67 (8/12) 78 (7/9) <75 80 (4/5) 100 (3/3) ORR: % (n) PD-L1 ≥ 5 PD-L1 < 5 CLDN18.2 ≥ 75 80 (8/10) 0 (0/2) CLDN18.2 < 75 100 (1/1) 75 (3/4) Durability: 8 of 17 patients remained on study treatment and the longest treatment duration was 13.3 months as of the data cutoff Median follow-up was 9.0 months across all dose levels as of the data cutoff Safety: Treatment-related adverse events (TRAEs) leading to discontinuation of any treatment were 12% (two patients), five patients had progressive disease, two patients withdrew from the study for social reasons No dose limiting toxicities (DLT) were observed and a maximum tolerated dose (MTD) was not reached Common TRAEs (≥10% of patients) were generally Grade 1 or Grade 2 including nausea, vomiting, infusion related reaction, fatigue, decreased appetite, diarrhea, abdominal pain, chills, dyspepsia and gastritis Grade 3 TRAEs attributed to givastomig were rare, with single cases of abdominal pain, ALT/AST increases, gastritis, and infusion related reaction Four cases of Grade 3 and two cases of Grade 4 treatment-related neutropenia were observed driven by an early restriction on prophylaxis use of G-CSF, which has been subsequently lifted. The neutropenia cases were primarily attributed to mFOLFOX6 in the 8 mg/kg cohorts No Grade 5 TRAEs were reported About Givastomig Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (1L) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents. An ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company's differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. For more information, please visit and follow us on LinkedIn and X. I-Mab Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will', 'expects', 'believes', 'designed to', 'anticipates', 'future', 'intends', 'plans', 'potential', 'estimates', 'confident', and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the 'Risk Factors' section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. I-Mab Investor & Media ContactsPJ KelleherLifeSci Advisors+1-617-430-7579 [email protected] [email protected]
Business Upturn
3 hours ago
- Business Upturn
ZA Miner Emerges as a Top Choice for Short-Term Crypto Passive Income in 2025
By GlobeNewswire Published on July 2, 2025, 20:28 IST London, United Kingdom, July 02, 2025 (GLOBE NEWSWIRE) — With the surge in interest around passive income solutions amid global inflation and volatile crypto markets, ZA Miner has quickly positioned itself as a trusted, high-growth platform in the mobile cloud mining space. The UK-registered company has recorded significant user growth in the first half of 2025, surpassing 1 million global users and drawing attention from both first-time crypto earners and seasoned investors looking for shorter, automated returns. While most platforms focus on long lock-in periods or complex mining setups, ZA Miner is taking a different route—short-term contracts, daily payouts, and full automation —making it easier for individuals to earn without needing technical knowledge, trading experience, or expensive hardware. What Makes ZA Miner Different? ZA Miner provides a plug-and-play approach to crypto mining. Its platform is accessible via mobile and web, allowing users to activate a mining contract in just a few clicks and start receiving daily profits without doing anything in return. Here's what stands out: Short-Term Contracts : One of the few platforms offering high-yield contracts as short as 1–3 days, making it ideal for users looking for fast turnover and limited risk. : One of the few platforms offering high-yield contracts as short as 1–3 days, making it ideal for users looking for fast turnover and limited risk. Daily Income Payouts : Users earn and withdraw daily, avoiding long lock-ins or delayed earnings. : Users earn and withdraw daily, avoiding long lock-ins or delayed earnings. Green Energy Infrastructure : All mining is powered by renewable energy sources, primarily solar and hydro, aligning with ESG-focused investor values. : All mining is powered by renewable energy sources, primarily solar and hydro, aligning with ESG-focused investor values. Real-Time Monitoring: Users can check earnings, balance, and contract performance through the official app or web dashboard, anytime. Security First: Enterprise-Level Protections Security is a priority at ZA Miner. The platform uses: Bank-level EV SSL encryption Cloudflare® anti-DDoS protections Cold wallet storage for digital assets Two-factor authentication (2FA) across accounts This infrastructure provides users with peace of mind, especially those who are new to cloud mining or investing online. Platform audits and transparent income reporting are conducted regularly to meet international compliance and financial safety standards. Strong User Growth in 2025 ZA Miner's rapid user adoption has been one of its most notable achievements this year. According to internal reports, over 1 million users joined globally between January and June 2025, with strong traction coming from Asia, Africa, and Eastern Europe. This momentum reflects growing demand for simplified, mobile-first crypto-earning platforms, especially as younger investors and gig workers look for scalable alternatives to traditional finance. Who Should Use ZA Miner? ZA Miner is ideal for: First-time crypto users who want to test passive income tools without financial risk who want to test passive income tools without financial risk Side-income seekers who want short contracts with quick returns who want short contracts with quick returns Professionals looking to diversify income without trading or market timing looking to diversify income without trading or market timing Green-conscious investors who value clean-energy-backed platforms who value clean-energy-backed platforms Crypto investors wanting a fully automated way to earn from coins like BTC, ETH, DOGE, LTC, XRP, and USDT With low starting capital and risk-free trial contracts available for new users, ZA Miner lowers the barriers significantly for anyone curious about crypto mining but hesitant to dive in with large upfront investments. Short-Term Contract Here are a few current options available directly on the platform: Plan Type Cost Duration Total Return Trial Plan $100 (free for new users) 1 Day $102 Starter $1,000 3 Days $1,086 Advanced $7,000 7 Days $8,400 Enterprise $58,000 30 Days $93,200 All plans are automated, and earnings are credited daily. Users can withdraw anytime or reinvest for compound returns. Getting Started is Simple New users receive a $100 mining bonus after registering, which can be used to activate a trial plan immediately. Register at your contractMonitor or reinvest your daily earnings Manage everything through ZA Miner's mobile app (iOS and Android supported) ZA Miner is Redefining Crypto Mining for the Everyday User At a time when financial independence is top of mind for many, ZA Miner offers a practical, accessible, and low-risk solution to participate in the crypto economy. With short-term flexibility, high security, and rapid growth to back its credibility, ZA Miner stands out as one of the most relevant crypto platforms in 2025. Official Website: Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
